Please login to the form below

Not currently logged in
Email:
Password:

chronic lymphocytic leukaemia

This page shows the latest chronic lymphocytic leukaemia news and features for those working in and with pharma, biotech and healthcare.

Lilly drops Hanmi-partnered arthritis drug

Lilly drops Hanmi-partnered arthritis drug

The first BTK inhibitor to reach the market was Johnson &Johnson (J&J) and Pharmacyclics' Imbruvica (ibrutinib), but this has been introduced initially for blood cancers including chronic lymphocytic leukaemia (CLL)

Latest news

More from news
Approximately 12 fully matching, plus 95 partially matching documents found.

Latest Intelligence

  • Europe vs the US: New drug product approvals Europe vs the US: New drug product approvals

    Tecentriq (for the treatment of urothelial carcinoma, only approved in the US), and Venclexta (for the treatment of chronic lymphocytic leukaemia, approved in the EU and US).

  • Deal Watch June 2016 Deal Watch June 2016

    Paying $150m upfront Novartis gains access to XmAb14045 being developed for acute myeloid leukaemia (AML) and XmAb13676 in development for B-cell malignancies. ... on B-cell tumor cells, including chronic lymphocytic leukaemia (CLL) and non-Hodgkin

  • Astellas: Ten years young Astellas: Ten years young

    Meanwhile, the company has Levact (bendamustine) for chronic lymphocytic leukaemia, non-Hodgkin's lymphomas and multiple myeloma, giving it broader interests in the area.

  • Deal Watch November 2015 Deal Watch November 2015

    379. Cellectis. Servier. Option exercise. UCART19, CAR-T allogeneic immunotherapy being tested for chronic lymphocytic leukaemia and acute lymphoblastic leukaemia.

  • Medius Deal Watch table for February 2015 Medius Deal Watch table for February 2015

    Abbreviations:. IDO, Indoleamine-2, 3-dioxygenase; TDO, Tryptophan-2, 3- dioxygenase. COPD, chronic obstructive pulmonary disease. ... CLL, chronic lymphocytic leukaemia; NHL, indolent non-Hodgkin lymphoma.

More from intelligence
Approximately 0 fully matching, plus 10 partially matching documents found.

Latest from PMHub

  • Therapy Watch expands oncology and IBD portfolios

    Chronic Myelogenous Leukaemia (CML) study in the US. ... Therapy Watch CML is part of a wider oncology portfolio which already covers Chronic Lymphocytic Leukaemia (CLL), Non-Hodgkin's Lymphoma (NHL), Melanoma, Non-Small Cell Lung Cancer (NSCLC),

  • Therapy Watch expands its oncology portfolio

    Therapy Watch SCCHN is part of a wider portfolio which covers Chronic Lymphocytic Leukaemia (CLL), Non-Hodgkin's Lymphoma (NHL), Melanoma, Non-Small Cell Lung Cancer (NSCLC), Prostate Cancer (PCa), Renal

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
An agency called Owen

We’re an independent brand and marketing agency that believes our DNA is a little different from others. * A respectful,...

Latest intelligence

Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...
The Holy Grail of HCP Access
This is the data you need to gain access....

Infographics